263 related articles for article (PubMed ID: 16079892)
1. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
Falini B; Mecucci C; Tiacci E; Alcalay M; Rosati R; Pasqualucci L; La Starza R; Diverio D; Colombo E; Santucci A; Bigerna B; Pacini R; Pucciarini A; Liso A; Vignetti M; Fazi P; Meani N; Pettirossi V; Saglio G; Mandelli F; Lo-Coco F; Pelicci PG; Martelli MF;
N Engl J Med; 2005 Jan; 352(3):254-66. PubMed ID: 15659725
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
Falini B; Nicoletti I; Martelli MF; Mecucci C
Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
[TBL] [Abstract][Full Text] [Related]
7. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
Pasqualucci L; Liso A; Martelli MP; Bolli N; Pacini R; Tabarrini A; Carini M; Bigerna B; Pucciarini A; Mannucci R; Nicoletti I; Tiacci E; Meloni G; Specchia G; Cantore N; Di Raimondo F; Pileri S; Mecucci C; Mandelli F; Martelli MF; Falini B
Blood; 2006 Dec; 108(13):4146-55. PubMed ID: 16926285
[TBL] [Abstract][Full Text] [Related]
8. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
[TBL] [Abstract][Full Text] [Related]
10. The incidence and clinical significance of nucleophosmin mutations in childhood AML.
Brown P; McIntyre E; Rau R; Meshinchi S; Lacayo N; Dahl G; Alonzo TA; Chang M; Arceci RJ; Small D
Blood; 2007 Aug; 110(3):979-85. PubMed ID: 17440048
[TBL] [Abstract][Full Text] [Related]
11. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
[TBL] [Abstract][Full Text] [Related]
12. Identification of NPMc+ acute myeloid leukemia in bone marrow smears.
Bedekovics J; Rejtő L; Telek B; Kiss A; Hevessy Z; Ujfalusi A; Méhes G
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):73-8. PubMed ID: 22595947
[TBL] [Abstract][Full Text] [Related]
13. Role of nucleophosmin in acute myeloid leukemia.
Meani N; Alcalay M
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1283-94. PubMed ID: 19761432
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
15. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
Rau R; Brown P
Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
[TBL] [Abstract][Full Text] [Related]
17. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.
Alcalay M; Tiacci E; Bergomas R; Bigerna B; Venturini E; Minardi SP; Meani N; Diverio D; Bernard L; Tizzoni L; Volorio S; Luzi L; Colombo E; Lo Coco F; Mecucci C; Falini B; Pelicci PG
Blood; 2005 Aug; 106(3):899-902. PubMed ID: 15831697
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.
Mariano AR; Colombo E; Luzi L; Martinelli P; Volorio S; Bernard L; Meani N; Bergomas R; Alcalay M; Pelicci PG
Oncogene; 2006 Jul; 25(31):4376-80. PubMed ID: 16501600
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
Andresen V; Erikstein BS; Mukherjee H; Sulen A; Popa M; Sørnes S; Reikvam H; Chan KP; Hovland R; McCormack E; Bruserud Ø; Myers AG; Gjertsen BT
Cell Death Dis; 2016 Dec; 7(12):e2497. PubMed ID: 27906185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
